What question did this study set out to answer?

The aim was to evaluate the efficacy of pertuzumab and trastuzumab in patients with ERBB2/3-altered cancers.

May 3, 2026

Pertuzumab and Trastuzumab in Patients With ERBB2/3-Altered Urothelial or Ovary/Fallopian Tube Cancer: Results From the Targeted Agent and Profiling Utilization Registry Study.

Key Points

The aim was to evaluate the efficacy of pertuzumab and trastuzumab in patients with ERBB2/3-altered cancers.
Utilized Simon's two-stage design with a null disease control rate of 15%.
Primary endpoint was disease control defined as objective response or stable disease for at least 16 weeks.
Secondary endpoints included overall response, progression-free survival, and safety.
Achieved a disease control rate of 35% (p-value ≤ 0.10).
Observed at least one grade 3-5 adverse event in six patients.
No significant efficacy in patients with ovarian or fallopian tube cancer.

Abstract

PURPOSE: alterations treated with pertuzumab plus trastuzumab (P + T) are reported. METHODS: alterations, and no standard treatment options. The primary end point was disease control (DC), defined as objective response (OR) or stable disease (SD) of at least 16+ weeks duration. Simon's two-stage design is based on a null DC rate of 15% versus 35% (power = 0.85; α = .10). Secondary end points included OR, progression-free survival (PFS), overall survival (OS), duration of response, duration of SD, and safety. RESULTS: = .35). Six patients had at least one grade 3-5 adverse event (AE) or serious AE at least possibly related to treatment. CONCLUSION: alterations, but not in patients with OC/FTC.

Pertuzumab and Trastuzumab in Patients With ERBB2/3-Altered Urothelial or Ovary/Fallopian Tube Cancer: Results From the Targeted Agent and Profiling Utilization Registry Study.

Key Points

Abstract

Cite This Study

Also Consider

Also Consider